AES 2025

December 05-09, 2025
Atlanta, GA, USA

American Epilepsy Society Annual Meeting 2025
Explore more Neuroscience congress materials
Material Type

Results(8)

Epilepsy
Real-World Effectiveness of Cannabidiol on Antiseizure Medication Cycling, Polypharmacy, and Healthcare Resource Utilization: A US Claims Analysis
Author(s): Leah Burn, Rachel Faller, Kara Bennet et al.
A Population Health Study of Patients Prescribed Cannabidiol in the Epilepsy Learning Healthcare System (ELHS) Registry
Author(s): Kathleen M. Farrell, Jhansi Anjana Rayapureddy, Rebeka Bustamante Rocha et al.
Effectiveness of Cannabidiol in Patients With Rare Epilepsies Compared to External Placebo Control: A Post Hoc Analysis From the Expanded Access Program
Author(s): Yong Park, Teresa Greco, Kelly C. Simontacchi et al.
An Assessment of Acute Pharmacodynamic Drug-Drug Interactions Between Cannabidiol and Cenobamate in a Mouse Model of Generalized Tonic Seizures
Author(s): Rohini R. Rana, William H. Hind, Pabitra H. Patra et al.
Real-World Polypharmacy and Healthcare Resource Utilization After Early-Line Treatment With Cannabidiol for Lennox-Gastaut Syndrome, Dravet Syndrome, and Tuberous Sclerosis Complex
Author(s): Arthur Sillah, Leah Burn, Rachel Faller et al.
Cannabidiol Efficacy in Patients With Lennox-Gastaut Syndrome With Developmental and Epileptic Encephalopathy-Associated Genetic Variants: A Subgroup Analysis
Author(s): Elizabeth A. Thiele, Michael Boffa, Daniel Checketts et al.
Tuberous Sclerosis Complex (TSC)–Associated Neuropsychiatric Disorders (TAND) Outcomes Following Adjunctive Cannabidiol (CBD) Treatment: 6-Month Intermediate Analysis of the EpiCom Tria
Author(s): Agnies van Eeghen, Sarah M.L. Wilson, Stevie Roszkowski et al.
Phase 1, Open-Label, Fixed-Sequence, Bidirectional, Pharmacokinetic Drug-Drug Interaction Study Between Cannabidiol and Cenobamate in Healthy Adult Participants
Author(s): Arjun Vijan, Hongwei Xue, Patricia Chandler et al.